REGN7508 vs. ApixabanStroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation

Sponsor:

Regeneron Pharmaceuticals

Code:

NCT07626411

Conditions

Atrial Fibrillation (AF)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

REGN7508

Apixaban

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-02. This information was provided to ClinicalTrials.gov by Regeneron Pharmaceuticals on 2026-08-25.